Quick Answer
Voyager Therapeutics, Inc. reported Research And Development Expense of $134.67 million for the year ending 2025.
- Voyager Therapeutics, Inc. showed an increase of +5.7% in Research And Development Expense from 2024 to 2025.
- This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Voyager Therapeutics, Inc.'s Research And Development Expense has grown by 1,413.5%.
- Historical annual values: Fiscal year 2025: $134.67 million | Fiscal year 2024: $127.37 million | Fiscal year 2023: $92.17 million | Fiscal year 2022: $60.76 million | Fiscal year 2021: $73.79 million | Fiscal year 2020: $108.75 million | Fiscal year 2019: $119.74 million | Fiscal year 2018: $64.91 million | Fiscal year 2017: $62.26 million | Fiscal year 2016: $42.25 million | Fiscal year 2015: $27.68 million | Fiscal year 2014: $8.90 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: